Hereditary Cancer Panel denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for hereditary cancer panel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Cites "Not FDA-Approved" for Hereditary Cancer Panel Testing

This denial reason is frequently misapplied to genetic laboratory tests. The FDA regulates certain laboratory-developed tests and in-vitro diagnostic devices, but many hereditary cancer panels are offered as laboratory-developed tests (LDTs) under CLIA certification rather than through an FDA premarket approval or clearance pathway. UHC may incorrectly apply a pharmaceutical "FDA-approved" standard to a laboratory service that is not subject to that approval framework. Alternatively, UHC may be flagging the test because it was recently reclassified by FDA or because the specific panel configuration lacks a discrete FDA authorization number.

## Why This Denial Is Appealable

Denials based on a misapplied FDA-approval standard are directly contestable. CLIA-certified laboratories are federally regulated and authorized to offer LDTs. If the test is performed at an accredited laboratory under CLIA — which nearly all major hereditary cancer testing labs are — the "not FDA-approved" rationale does not accurately describe the applicable regulatory framework. Your appeal should correct this factual and regulatory error head-on.

## Your Federal Appeal Rights

• Internal appeal: File under ERISA §503 (employer plans) or applicable state insurance law. Explicitly challenge the factual basis of the denial — the "not FDA-approved" characterization — and request the specific regulatory citation UHC relied upon.
• External review: Under ACA §2719, independent external review is available after the internal appeal is exhausted. Standard window is approximately four months. If the clinical situation is time-sensitive, request expedited review.

## Concrete Appeal Steps and Timeline

1. Obtain the laboratory's CLIA certificate and CAP accreditation documentation (available directly from the testing lab). 2. Request from UHC in writing the specific regulatory basis for the "not FDA-approved" determination — which FDA database entry or policy document they relied upon. 3. Have the ordering clinician and the laboratory's medical director jointly respond, clarifying the CLIA/LDT regulatory pathway. 4. Submit a Level 1 internal appeal disputing the factual and legal basis of the denial. 5. Escalate to external IRO review if the internal appeal is denied.

## Documentation to Gather

• Laboratory accreditation: CLIA certificate number, CAP accreditation letter, and applicable state laboratory license for the performing laboratory.
• Test regulatory status: A brief written statement from the laboratory's medical director or compliance team describing the regulatory pathway under which the test is offered.
• Clinical indication: Prescriber letter of medical necessity linking the test to the patient's documented personal and family history and explaining how results will guide management.
• UHC's own policy: The specific Medical Policy or Coverage Determination Guideline UHC cited — confirm it actually requires FDA device approval rather than CLIA certification.

## Criteria-Mapping Structure

Create a two-column table: left column lists each stated basis for UHC's denial; right column provides the factual rebuttal with supporting documentation citations. For a regulatory-basis appeal, the rebuttal must cite the specific federal statute (CLIA under CLIA '88, 42 U.S.C. §263a) and the testing laboratory's credentials. This precise framing signals to the reviewer — and to any IRO — that the denial rests on a factual error rather than a legitimate coverage determination.